Chief Medical Officer Chris Morabito resigns effective July 13, 2022

Fulcrum Therapeutics, Inc.

Chris Morabito, M.D., stepped down as Chief Medical Officer of Fulcrum Therapeutics.
Resignation effective July 13, 2022; he left to pursue another opportunity.
No replacement announced; departure not due to any disagreement with company.
Morabito's resignation follows no known operational or financial disputes.
Fulcrum did not provide details on interim CMO or search timeline.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chris Morabito, M.D.

Chief Medical Officer

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-07-13
Filed: July 11, 2022, 7:59 PM ET

On July 8, 2022, Chris Morabito, M.D., Chief Medical Officer of Fulcrum Therapeutics, Inc., or Fulcrum, notified Fulcrum of his resignation from this position and from his employment with Fulcrum, to be effective on July 13, 2022, in order to pursue a new opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Morabito, M.D. resigned as Chief Medical Officer at Fulcrum Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On July 8, 2022, Chris Morabito, M.D., Chief Medical Officer of Fulcrum Therapeutics, Inc., or Fulcrum, notified Fulcrum of his resignation from this position and from his employment with Fulcrum, to be effective on July 13, 2022, in order to pursue a new opportunity.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-191340

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.